Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis

Arthritis Care and Research

Volumn 70, Issue 3, 2018, Pages 409-419

  Schulert, Grant S ^a   Minoia, Francesca ^b   Bohnsack, John ^c   Cron, Randy Q ^d   Hashad, Soah ^e   KonÉ Paut, Isabelle ^f   Kostik, Mikhail ^g   Lovell, Daniel ^a   Maritsi, Despoina ^h   Nigrovic, Peter A ⁱ   Pal, Priyankar ^j   Ravelli, Angelo ^b   Shimizu, Masaki ^k   Stanevicha, Valda ^l   Vastert, Sebastiaan ^m   Woerner, Andreas ⁿ   de Benedetti, Fabrizio ^o   Grom, Alexei A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Tripoli Children's Hospital   (Libyan Arab Jamahiriya)

^f BICÊTRE HOSPITAL   (France)

^g SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^h UNIVERSITY OF ATHENS   (Greece)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j INSTITUTE OF CHILD HEALTH   (India)

^k KANAZAWA UNIVERSITY   (Japan)

^l RIGA STRADINS UNIVERSITY   (Latvia)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁿ UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^o BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; ASPARTATE AMINOTRANSFERASE; CANAKINUMAB; FERRITIN; FIBRINOGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CYTOKINE;

ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOLOGICAL THERAPY; CLINICAL FEATURE; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FERRITIN BLOOD LEVEL; FEVER; FIBRINOGEN BLOOD LEVEL; HUMAN; LABORATORY TEST; MACROPHAGE ACTIVATION SYNDROME; MORTALITY RATE; ONSET AGE; PLATELET COUNT; SYSTEMATIC REVIEW; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; THERAPY EFFECT; TREATMENT OUTCOME; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHILD; FEMALE; IMMUNOLOGY; JUVENILE RHEUMATOID ARTHRITIS; MALE; PREDICTIVE VALUE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; MACROPHAGE ACTIVATION SYNDROME; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 85041195912     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23277     Document Type: Article

References (50)

1. Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med 2015;66:145–59.
2. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 2016;12:259–68.
3. Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014;66:3160–9.
4. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012;13:289–98.
5. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:965–71.
6. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34:1133–8.
7. Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A 2015;112:15970–5.
8. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev 2016;15:931–4.
9. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011;7:416–26.
10. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479–86.
11. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747–54.
12. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007;204:2131–44.
13. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158–63.
14. Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 2014;66:1034–43.
15. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012;64:1001–10.
16. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396–406.
17. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385–95.
18. Grom AA, Ilowite NT, Pascual V, Brunner HI, Martini A, Lovell D, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol 2016;68:218–28.
19. Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol 2015;42:712–22.
20. Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012;58:287–94.
21. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31.
22. Davì S, Minoia F, Pistorio A, Horne A, Consolaro A, Rosina S, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014;66:2871–80.
23. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146:598–604.
24. Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Arthritis Rheumatol 2016;68:566–76.
25. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J 2014;12:13.
26. Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 2016;75:1654–60.
27. Macaubas C, Wong E, Zhang Y, Nguyen KD, Lee J, Milojevic D, et al. Altered signaling in systemic juvenile idiopathic arthritis monocytes. Clin Immunol 2016;163:66–74.
28. Sikora KA, Fall N, Thornton S, Grom AA. The limited role of interferon-γ in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness. Arthritis Rheum 2012;64:3799–808.
29. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014;6:a016295.
30. Drucker C, Gewiese J, Malchow S, Scheller J, Rose-John S. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun 2010;34:29–37.
31. Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 2014;41:759–67.
32. Kessler EA, Vora SS, Verbsky JW. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr Rheumatol Online J 2012;10:30.
33. Ray A, Prefontaine KE, Ray P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem 1994;269:12940–6.
34. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008;4:615–20.
35. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011;50:417–9.
36. Iwai A, Naniwa T, Tamechika S, Maeda S. Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis. Mod Rheumatol 2017;27:529–32.
37. Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol 2015;160:277–81.
38. Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 2014;46:1140–6.
39. Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology (Oxford) 2015;54:1507–17.
40. Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, et al. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis 2017;76:166–72.
41. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004;104:735–43.
42. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545–55.
43. Woerner A, Uettwiller F, Melki I, Mouy R, Wouters C, Bader-Meunier B, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open 2015;1:e000036.
44. Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 2013;65:2486–96.
45. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009;15:161–4.
46. Kapovic A, Gagro A. Interleukin-6 levels as indicator of macrophage activation syndrome/relapse in systemic juvenile idiopathic arthritis during anakinra or tocilizumab treatment. Cytokine 2012;59:569.
47. Kostik MM, Likhacheva T, Chikova IA, Buchinskaya NV, Abramova N, Kalashnikova OV, et al. Higher-dose canakinumab therapy for refractory macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: two case reports. Pediatr (St Petersburg) 2014;5:14–9.
48. Kostik MM, Dubko MF, Masalova VV, Snegireva LS, Kornishina TL, Chikova IA, et al. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2015;13:4.
49. Koné-Paut I, Retornaz K, Garnier JM, Bader-Meunier B. Visceral leishmaniasis in a patient with systemic juvenile arthritis treated by IL-1RA agonist (anakinra). Clin Exp Rheumatol 2007;25:119.
50. De Benedetti F, Schneider R, Weitzman S, Devlin C, Daimaru K, Yokota S, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Pediatr Rheumatol Online J 2014;12:55.